The purpose of this research is to test the safety of NXC-201 (a CAR-T cell targeting the BCMA protein) at different doses in participants with relapsed/refractory AL amyloidosis, and to confirm the best dose for further testing. In addition, the study will evaluate the effectiveness of NXC-201 in treating relapsed/refractory AL amyloidosis

The purpose of this study is to determine if epcoritamab can be used to treat patients with previously treated WM.

Have you been diagnosed with advanced cancer that cannot be removed by surgery or has spread to a different part of the body (metastasis)? Has your disease has been getting worse on standard of care cancer treatment? If so, you may be able to take part in a research study looking at whether the experimental study drug, AI-081, is safe and well tolerated, and whether it is effective in treating advanced or metastatic cancer.

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.

To determine the anti-proliferative effect of tirzepatide on the endometrium of endometrial cancer (EC) patients .

This trial seeks to enroll patients diagnosed with HER2-negative (HER2- low or HER2-0)- MBC who are starting treatment with T-DXd. The purpose is to determine if the test used for HER2+ MBC also works for HER2-low MBC. By participating in this trial, you are contributing to information that may improve the care of future patients with HER2-negative (HER2- low or HER2-0)- MBC. This trial does not require additional biopsies. Only tissue left over from a standard-of-care procedure will be used. The study team will access your medical record to review routine imaging test results as well as track your response to your treatment. Your breast cancer care will be managed by your oncologist, and you won't need to interact with the study team for direct care. No extra visits with the study team are required, except possibly for the initial enrollment.

The purpose of this study is to find the maximum tolerated dose and the recommended Phase 2 dose of IOV-3001 infusion given after lifileucel to participants with advanced (unresectable or metastatic) melanoma who meet the requirements for treatment with lifileucel. The study duration for each participant will be up to about 6 months (Phase 1, Part 1) or 5 years (Phase 1, Part 2) after the lifileucel dose. Study intervention begins with surgery to get a tumor sample that will be used to make lifileucel

The main purpose of this study is to test the safety of a gene therapy. Scientists have created a gene in the laboratory that could be transferred to the cells in the body. This gene carries information to tell the cells how to make an antibody (protein). The antibody (protein) is very similar to an antibody (protein) called blinatumomab. Blinatumomab is an FDA-approved treatment for relapsed or refractory B-cell ALL. This gene therapy is not approved by the FDA, therefore is it experimental. This study tests different doses of the gene therapy to see which dose is safer in people since it has not been tested in people yet.

Do you have early-stage breast cancer that is considered low-risk by your doctor? If yes, you might be able to join a research study. In this study, we are testing if taking a lower dose of the medicine tamoxifen is a better treatment for you than the usual hormone therapy.

Have you been diagnosed with Stage 4 HER2 positive (HER2+) breast cancer? If so, you may be able to take part in a research study to test the safety and effectiveness of a sequence of drugs (a taxane plus trastuzumab plus pertuzumab followed by trastuzumab Deruxtecan, followed by tucatinib plus Ado-trastuzumab emtansine (T-DM1), followed by trastuzumab plus pertuzumab plus tucatinib) to learn whether the treatment works in treating your type of cancer. The study will help us understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for patients who receive this therapy.